GSK heart drug misses endpoint

Share this article:

GlaxoSmithKline's Phase-III heart drug darapladib failed to hit its primary endpoint in its second late-stage study. The company said in Tuesday's announcement that the safety profile had no major concerns but that the Lp-PLA2 inhibitor did not reduce major coronary events compared to placebo when added to standard of care.

This was the second Phase-III study among patients who had experienced acute coronary syndrome.

Reuters noted in March that success would have validated GSK's 2012 purchase of Human Genome Sciences that brought the experimental drug in-house. “Darapladib was one of the reasons behind its $3.6 billion acquisition,” Reuters noted. The news source also highlighted that HGS rejected GSK's earlier $2.6-billion bid because GSK underestimated darapladib's blockbuster potential.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.